JP2022513460A5 - - Google Patents

Info

Publication number
JP2022513460A5
JP2022513460A5 JP2021533530A JP2021533530A JP2022513460A5 JP 2022513460 A5 JP2022513460 A5 JP 2022513460A5 JP 2021533530 A JP2021533530 A JP 2021533530A JP 2021533530 A JP2021533530 A JP 2021533530A JP 2022513460 A5 JP2022513460 A5 JP 2022513460A5
Authority
JP
Japan
Prior art keywords
domain
polypeptide
item
items
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513460A (ja
JP7636650B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066223 external-priority patent/WO2020123938A1/en
Publication of JP2022513460A publication Critical patent/JP2022513460A/ja
Publication of JP2022513460A5 publication Critical patent/JP2022513460A5/ja
Priority to JP2024188998A priority Critical patent/JP2025010249A/ja
Application granted granted Critical
Publication of JP7636650B2 publication Critical patent/JP7636650B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533530A 2018-12-14 2019-12-13 二量体形成剤調節性免疫受容体複合体 Active JP7636650B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024188998A JP2025010249A (ja) 2018-12-14 2024-10-28 二量体形成剤調節性免疫受容体複合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779971P 2018-12-14 2018-12-14
US62/779,971 2018-12-14
US201962835659P 2019-04-18 2019-04-18
US62/835,659 2019-04-18
PCT/US2019/066223 WO2020123938A1 (en) 2018-12-14 2019-12-13 Dimerizing agent regulated immunoreceptor complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024188998A Division JP2025010249A (ja) 2018-12-14 2024-10-28 二量体形成剤調節性免疫受容体複合体

Publications (3)

Publication Number Publication Date
JP2022513460A JP2022513460A (ja) 2022-02-08
JP2022513460A5 true JP2022513460A5 (cg-RX-API-DMAC7.html) 2022-12-20
JP7636650B2 JP7636650B2 (ja) 2025-02-27

Family

ID=71077012

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533530A Active JP7636650B2 (ja) 2018-12-14 2019-12-13 二量体形成剤調節性免疫受容体複合体
JP2024188998A Pending JP2025010249A (ja) 2018-12-14 2024-10-28 二量体形成剤調節性免疫受容体複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024188998A Pending JP2025010249A (ja) 2018-12-14 2024-10-28 二量体形成剤調節性免疫受容体複合体

Country Status (8)

Country Link
US (1) US12516129B2 (cg-RX-API-DMAC7.html)
EP (1) EP3895052A4 (cg-RX-API-DMAC7.html)
JP (2) JP7636650B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210104772A (cg-RX-API-DMAC7.html)
CN (1) CN113366479A (cg-RX-API-DMAC7.html)
CA (1) CA3123084A1 (cg-RX-API-DMAC7.html)
IL (1) IL283897B1 (cg-RX-API-DMAC7.html)
WO (1) WO2020123938A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3084551A1 (en) 2017-12-14 2019-06-20 Bluebird Bio, Inc. Daric interleukin receptors
WO2020123947A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
WO2020227475A1 (en) 2019-05-08 2020-11-12 Bluebird Bio, Inc. Cll-1 targeted immunotherapies
WO2022099176A1 (en) * 2020-11-09 2022-05-12 2Seventy Bio, Inc. Aml targeted immunotherapies
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2022266075A1 (en) * 2021-06-14 2022-12-22 Caribou Biosciences, Inc. Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
CN113528455A (zh) * 2021-07-19 2021-10-22 广州百暨基因科技有限公司 表达嵌合抗原受体的γδT细胞
CN114736306B (zh) * 2022-03-01 2024-04-19 中国科学院深圳先进技术研究院 一种受化学调控的蛋白酶工具及其配套底物

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
CA2128511C (en) 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
HUT73101A (en) 1993-02-12 1996-06-28 Harvard College Method for regulating transcription of targeted genes and other biological events
US6972193B1 (en) 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
EP0737207B1 (en) 1994-01-11 2004-09-22 Dyax Corporation Inhibitors of human plasmin derived from the kunitz domains
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999036553A2 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
JP2002503667A (ja) 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
WO2010062966A2 (en) 2008-11-26 2010-06-03 The General Hospital Corporation Methods for inducing mixed chimerism
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
WO2011097456A2 (en) 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
JP5897035B2 (ja) 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド,ボルチモア 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
US20160015749A1 (en) 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
HK1220111A1 (zh) 2013-03-05 2017-04-28 Baylor College Of Medicine 人类t淋巴细胞中类肝素酶的表达
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
JP6966330B2 (ja) 2015-05-01 2021-11-17 インヒブルクス,インコーポレイティド Iii型分泌装置標的化分子
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
JP6894430B2 (ja) 2015-08-24 2021-06-30 セレクティスCellectis 統合された制御機能を有するキメラ抗原受容体
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
US20190241910A1 (en) * 2016-03-11 2019-08-08 Bluebird Bio, Inc. Genome edited immune effector cells
CA3020993A1 (en) 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CA3084551A1 (en) 2017-12-14 2019-06-20 Bluebird Bio, Inc. Daric interleukin receptors
WO2019118885A1 (en) 2017-12-14 2019-06-20 Bluebird Bio, Inc. Nkg2d daric receptors
CN111819682B (zh) 2018-03-26 2025-04-29 三菱综合材料株式会社 绝缘电路基板用接合体的制造方法及绝缘电路基板用接合体
WO2020052543A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
WO2020113063A1 (en) 2018-11-30 2020-06-04 Aleta Biotherapeutics Inc. Single domain antibodies against cll-1
WO2020123947A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020123933A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
AU2019397152A1 (en) 2018-12-14 2021-06-24 2Seventy Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
US20230192805A1 (en) 2019-01-14 2023-06-22 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
EP3966338A1 (en) 2019-05-08 2022-03-16 Inhibrx, Inc. Cd123 targeted immunotherapies
WO2020227475A1 (en) 2019-05-08 2020-11-12 Bluebird Bio, Inc. Cll-1 targeted immunotherapies
BR112022001194A2 (pt) 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
KR20220078607A (ko) 2019-09-12 2022-06-10 티씨알2 테라퓨틱스 인크. 융합 단백질들을 이용한 tcr 재프로그래밍을 위한 조성물 및 방법들
KR20220070501A (ko) 2019-09-30 2022-05-31 2세븐티 바이오, 인코포레이티드 이량체화제로 조절된 면역수용체 복합체
WO2021207613A1 (en) 2020-04-10 2021-10-14 2Seventy Bio, Inc. Frb antibodies

Similar Documents

Publication Publication Date Title
AU2021307614B2 (en) Engineered immune cell for allotransplantation
US20230390336A1 (en) Chimeric antigen receptor targeting cd7 and use thereof
JP2022116230A (ja) 免疫療法用改変細胞
US10098926B2 (en) Cell
JP7590034B2 (ja) Nkg2aを標的にする抗体及びその使用
FI3703750T3 (fi) B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja
IL318172A (en) Enhanced chimeric antigen receptors and uses thereof
JP2016531567A5 (cg-RX-API-DMAC7.html)
JP2021519580A5 (cg-RX-API-DMAC7.html)
EP4257610A1 (en) Ror1-targeting antibody and use thereof
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
JP2023514386A (ja) Nk阻害性分子を発現する遺伝子改変免疫細胞とその使用
WO2017176525A1 (en) Car having replicated binding motifs in a co-stimulatory domain
RU2016145958A (ru) Химерные антигенные рецепторы с mnd-промотором
JP2025513801A5 (cg-RX-API-DMAC7.html)
US20240082306A1 (en) Novel chimeric antigen receptor and use thereof
JP2023522038A5 (cg-RX-API-DMAC7.html)
JP2025511872A5 (cg-RX-API-DMAC7.html)
JP2024525727A5 (cg-RX-API-DMAC7.html)
JP2018537076A5 (cg-RX-API-DMAC7.html)
JP2024534471A5 (cg-RX-API-DMAC7.html)
JP2024534417A5 (cg-RX-API-DMAC7.html)
CN114539402B (zh) 靶向Claudin18.2的抗体及其用途
EP4613781A1 (en) Immune rejection-resistant engineered cell
WO2018045034A1 (en) Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain